

# ECM Therapeutics, Inc.

A Regenerative Medicine Company

## GI PRODUCT PIPELINE\*:

 **EsophaGel™**

EsophaGel™ is a mucoadhesive hydrogel being evaluated for its ability to reduce inflammation and promote neopithelialization of the esophageal mucosa. EsophaGel™ is being developed to mitigate stricture in the upper GI tract following endoscopic therapy (EMR or ESD).

 **GI-Gel™**

GI-Gel™ is being developed as a mucoadhesive hydrogel to reduce inflammation, promote neopithelialization, and mitigate stricture following EMR or ESD in the lower GI tract.

 **MucosaLift™**

MucosaLift™ is being developed to lift polyps, adenomas, early stage cancers, or other lesions in the GI tract, and to sustain cushion height to facilitate resection while avoiding GI bleeding or perforation.

 **MatriSeal™**

MatriSeal™ is being developed as an injectable hydrogel that can fill tortuous fistula tracts without extrusion for reinforcement and repair of anal, rectal, and enterocutaneous fistulas.

 **MatriStat™**

MatriStat™ is being developed as a hydrogel that promotes hemostasis.

\* Products listed above are in various stages of development and are not currently FDA approved or available for commercial use.



# ECM Therapeutics, Inc.

A Regenerative Medicine Company

ECM Therapeutics, Inc. is a regenerative medicine company that is developing and commercializing products derived from naturally occurring extracellular matrix (ECM)

- Proven technology & strong basic science: currently FDA approved in “sheet” and “powder” form
- ECM hydrogel: Next generation, less invasive, expanded applications vs. sheet and powder forms
- 11 issued US patents/41 patent applications pending US and ex-US
- cGMP Manufacturing capability
- First product to market Q1 2020 – MucosaLift™

## Stephen Badylak, DVM, PhD, MD

Founder & Chief Scientific Officer of ECM Therapeutics, Inc.

Dr. Badylak is also a Professor in the Department of Surgery, and Deputy Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh.

He has practiced both veterinary and human medicine and for the past 20 years has been fully engaged in research. Dr. Badylak holds over 70 U.S. patents, 300 patents worldwide, has authored more than 375 scientific publications and 40 book chapters, and has recently edited a textbook entitled “Host Response to Biomaterials”.

Dr. Badylak has founded two companies and either chaired or been a member of the Scientific Advisory Board to several major medical device companies. More than eight million patients have been treated with biologic scaffolds developed in the Badylak laboratory.